Mannitol Viaflo Baxter

Mannitol, the active ingredient in Mannitol Viaflo Baxter, is an osmotic diuretic presented as a solution for injection for intravenous use. It reduces intracranial pressure, promotes diuresis in acute renal failure, and is employed in clinical settings that require rapid fluid removal.

GNH USA supplies Mannitol Viaflo Baxter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Mannitol is used as an osmotic diuretic in several acute clinical conditions. - Intracranial hypertension: lowers intracranial pressure by drawing fluid from the brain into the vascular space. - Acute renal failure: enhances urine output to support renal clearance when kidney function is compromised. - Oliguric states: promotes diuresis in patients with low urine production to prevent fluid overload. - Glaucoma surgery: reduces intra‑ocular pressure during ophthalmic procedures.

Mannitol may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate discomfort often reported during infusion. - Nausea or vomiting: gastrointestinal upset occurring shortly after administration. - Thirst or dry mouth: sensation of increased dryness. - Transient hypotension: temporary drop in blood pressure during rapid infusion.

Serious or Rare Side Effects: - Acute renal failure: worsening kidney function in susceptible patients. - Pulmonary edema: fluid accumulation in the lungs due to rapid volume shifts. - Severe electrolyte disturbances: hypernatremia or hypokalemia requiring intervention. - Anaphylactic reaction: rare hypersensitivity requiring emergency treatment.

Before using Mannitol, clinicians should consider several safety measures. - Assess renal function: evaluate baseline creatinine and urine output before initiating therapy. - Monitor fluid balance: record input and output closely to avoid volume overload. - Check electrolytes: regularly measure serum sodium, potassium, and osmolality during treatment. - Adjust infusion rate: infuse slowly to reduce risk of hypotension and cardiac stress. - Avoid in patients with severe dehydration: risk of exacerbating hypovolemia. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mannitol can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Loop diuretics (e.g., furosemide): may cause excessive diuresis and electrolyte loss. - Nephrotoxic agents (e.g., aminoglycosides, amphotericin B): increase risk of renal impairment. - Insulin or oral hypoglycemics: osmotic shifts can potentiate hypoglycemia. - Hypertonic solutions: concurrent use can lead to severe hyperosmolar states.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may enhance renal effects and affect blood pressure. - Antihypertensives: additive hypotensive effect during rapid infusion. - Lithium: altered renal clearance may increase lithium levels.